Asbestos Diseases Research Institute, Sydney, Australia.
Asbestos Diseases Research Institute, Sydney, Australia; School of Medicine, University of Sydney, Sydney, Australia.
J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4.
INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM is characterized by frequent chromosomal deletions of tumor suppressors, including microRNAs. MiR-137 plays a tumor suppressor role in other cancers, so the aim of this study was to characterize it and its target Y-box binding protein 1 (YBX1) in MPM. METHODS: Expression, methylation, and copy number status of miR-137 and its host gene MIR137HG were assessed by polymerase chain reaction. Luciferase reporter assays confirmed a direct interaction between miR-137 and Y-box binding protein 1 gene (YBX1). Cells were transfected with a miR-137 inhibitor, miR-137 mimic, and/or YBX1 small interfering RNA, and growth, colony formation, migration and invasion assays were conducted. RESULTS: MiR-137 expression varied among MPM cell lines and tissue specimens, which was associated with copy number variation and promoter hypermethylation. High miR-137 expression was linked to poor patient survival. The miR-137 inhibitor did not affect target levels or growth, but interestingly, it increased miR-137 levels by means of mimic transfection suppressed growth, migration, and invasion, which was linked to direct YBX1 downregulation. YBX1 was overexpressed in MPM cell lines and inversely correlated with miR-137. RNA interference-mediated YBX1 knockdown significantly reduced cell growth, migration, and invasion. CONCLUSIONS: MiR-137 can exhibit a tumor-suppressive function in MPM by targeting YBX1. YBX1 knockdown significantly reduces tumor growth, migration, and invasion of MPM cells. Therefore, YBX1 represents a potential target for novel MPM treatment strategies.
简介:恶性胸膜间皮瘤(MPM)是一种与石棉暴露有关的侵袭性恶性肿瘤。在基因组水平上,MPM 的特征是肿瘤抑制因子的频繁染色体缺失,包括 microRNAs。miR-137 在其他癌症中发挥肿瘤抑制作用,因此本研究旨在研究其在 MPM 中的特征及其靶基因 Y-box 结合蛋白 1(YBX1)。 方法:通过聚合酶链反应评估 miR-137 和其宿主基因 MIR137HG 的表达、甲基化和拷贝数状态。荧光素酶报告基因实验证实了 miR-137 与 Y-box 结合蛋白 1 基因(YBX1)之间的直接相互作用。转染 miR-137 抑制剂、miR-137 模拟物和/或 YBX1 小干扰 RNA 后,进行细胞生长、集落形成、迁移和侵袭实验。 结果:MPM 细胞系和组织标本中的 miR-137 表达存在差异,与拷贝数变异和启动子高甲基化有关。高 miR-137 表达与患者预后不良相关。miR-137 抑制剂不影响靶基因水平或细胞生长,但有趣的是,通过模拟物转染增加 miR-137 水平会抑制生长、迁移和侵袭,这与直接下调 YBX1 有关。YBX1 在 MPM 细胞系中过表达,与 miR-137 呈负相关。RNA 干扰介导的 YBX1 敲低显著降低了细胞生长、迁移和侵袭。 结论:miR-137 通过靶向 YBX1 在 MPM 中表现出肿瘤抑制功能。YBX1 敲低显著降低了 MPM 细胞的肿瘤生长、迁移和侵袭。因此,YBX1 代表了新的 MPM 治疗策略的潜在靶点。
J Thorac Oncol. 2013-10
Oncotarget. 2015-9-15
Oncogene. 2013-11-18
J Thorac Oncol. 2016-1
Front Oncol. 2025-7-29
Biomolecules. 2024-7-22
Front Med (Lausanne). 2024-2-8
J Cancer Metastasis Treat. 2022